Trial · NCT02158052
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
NCT02158052, Not applicable, Completed, Massachusetts General Hospital; results first posted 2022-12-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease. Trials, record NCT02158052. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02158052
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
- NCT number
- NCT02158052
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Multiple Myeloma, Amyloidosis
- Interventions
- Tacrolimus, Equine Anti-thymocyte globulin, Kidney transplant from a related donor, Bone marrow transplant from a related donor, Total body irradiation 400 centigray (200 cGy X 2)
- First posted
- 2014-06-06
- Last updated
- 2022-12-13
- Results first posted
- 2022-12-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant | 6 Months | The Primary Outcome is: the incidence of renal allograft rejection at 6 months post-transplant |
| Secondary | Anti-Tumor Response Rate | 3 years | This is measurement is summarized via bone marrow biopsy results and blood assays through 3 years. Anti-tumor response is assessed according to Center for International Blood and Marrow Transplant Research (CIBMTR.org) criteria. For multiple myeloma, based on assessment of serum and urine immunofixation, the presence or absence of soft tissue plasmacytomas and analyses of bone marrow aspirate and biopsy samples, response categories include stringent complete remission (sCR), complete remission (CR), near CR (nCR) very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). For AL amyloidosis, based on assessment of serum and urine immunofixation and serum free light chain ratio, hematologic response categories include complete response, very good partial response, partial response, no response/stable disease and progressive disease. Organ responses are also assessed according to organ specific criteria. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant | 6 Months | One bone marrow/kidney transplant recipient was enrolled and treated on this trial. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Anti-Tumor Response Rate | 3 years | One bone marrow/kidney recipient was enrolled and treated on this trial. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant | Bone Marrow and Kidney RECIPIENTS | 1 | Participants | ||
| Anti-Tumor Response Rate | Bone Marrow and Kidney RECIPIENTS | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bone Marrow and Kidney RECIPIENTS | 1 | |
| Overall Study | STARTED | Bone Marrow and Kidney DONORS | 1 | |
| Overall Study | COMPLETED | Bone Marrow and Kidney RECIPIENTS | 1 | |
| Overall Study | COMPLETED | Bone Marrow and Kidney DONORS | 1 | |
| Overall Study | NOT COMPLETED | Bone Marrow and Kidney RECIPIENTS | 0 | |
| Overall Study | NOT COMPLETED | Bone Marrow and Kidney DONORS | 0 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Perinephric hematoma | Renal and urinary disorders | Bone Marrow and Kidney RECIPIENT | 1 | 1 | 1 |
| other | Perinephric hematoma | Renal and urinary disorders | Bone Marrow and Kidney DONOR | 1 | ||
| other | Abdominal pain | Gastrointestinal disorders | Bone Marrow and Kidney RECIPIENT | 1 | 1 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Bone Marrow and Kidney DONOR | 1 | ||
| serious | Acute kidney injury | Renal and urinary disorders | Bone Marrow and Kidney RECIPIENT | 1 | 1 | 1 |
| serious | Acute kidney injury | Renal and urinary disorders | Bone Marrow and Kidney DONOR | 1 | ||
| serious | Hematopoietic graft rejection | Blood and lymphatic system disorders | Bone Marrow and Kidney RECIPIENT | 1 | 1 | 1 |
| serious | Hematopoietic graft rejection | Blood and lymphatic system disorders | Bone Marrow and Kidney DONOR | 1 | ||
| serious | Aspergillosis | Respiratory, thoracic and mediastinal disorders | Bone Marrow and Kidney RECIPIENT | 1 | 1 | 1 |
| serious | Aspergillosis | Respiratory, thoracic and mediastinal disorders | Bone Marrow and Kidney DONOR | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bone Marrow and Kidney RECIPIENT | 0 | 1 |
| Total, all-cause mortality | Bone Marrow and Kidney DONOR | 0 | 1 |
| Total, other adverse events | Bone Marrow and Kidney RECIPIENT | 1 | 1 |
| Total, other adverse events | Bone Marrow and Kidney DONOR | 0 | 1 |
| Total, serious adverse events | Bone Marrow and Kidney RECIPIENT | 1 | 1 |
| Total, serious adverse events | Bone Marrow and Kidney DONOR | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Bone Marrow and Kidney RECIPIENT vs Bone Marrow and Kidney DONOR: deaths from any cause | Trial comparisons |
| Bone Marrow and Kidney RECIPIENT vs Bone Marrow and Kidney DONOR: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02158052
GET https://conductscience.org/api/trials/v1/NCT02158052/registered